Citigroup Begins Covering Advanced Accelerator Applications (NASDAQ:AAAP) Stock. “Shares to Hit $32.0”

Share

Why Has Citigroup Given Advanced Accelerator Applications (NASDAQ:AAAP) a $32.0 Price Target

Research analysts at Citigroup have commenced coverage coverage on shares of Advanced Accelerator Applications (NASDAQ:AAAP) in an analyst note finalized on 7 December. The equities firm set “Buy” rating on the stock. Citigroup’s target of $32.0 suggests potential of 20.75% from the stock’s last stock close.

It is down 6.00% since November 7, 2015 and is uptrending. It has outperformed by 7.08% the S&P500.

Citigroup Begins Covering Advanced Accelerator Applications (NASDAQ:AAAP) Stock. “Shares to Hit $32.0”

Advanced Accelerator Applications SA is a radiopharmaceutical firm that develops, produces and sells molecular nuclear medicine , diagnostic and therapeutic products. The company has a market cap of $1.01 billion. The Company’s lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs). It currently has negative earnings. The Firm has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products.

According to Zacks Investment Research, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France.” Get a free copy of the Zacks research report on Advanced Accelerator Application SA(ADR) (AAAP).

COMMENTS: